MAMenna M. Aboelkhier

Menna M. Aboelkhier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Menna M. Aboelkhier has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transcranial alternating current stimulation for chronic insomnia: a meta-analytic evaluation of sleep restoration and safety in adults

    by Yehia Nabil, Nourhan Hatem, Menna M. Aboelkhier, Anas Mansour, Kholoud Elsamman, Salma Allam, Aya Samy, Kiro Ehab, Ahmed Noufal, Ahmad Alkheder

    Chronic insomnia affects approximately one-third of adults globally, imposing substantial health burdens with limited effective treatments. Transcranial al


  • Open Access

    Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis

    by Mohamed Abo Zeid, Amr Elrosasy, Mohamad Ali Farho, Mohamed Rifai, Menna M. Aboelkhier, Mohamed Nabil Elkhrashy, Ahmed Hamdy Zabady, Mohamed Samir A. Zaki, Eman Mostafa Hamed, Samy A. Dawood, et al.

    Background: Healive is an inactivated vaccine for hepatitis A virus developed in China and was found to be well-tolerated and highly immunogenic in adults and children. It is our aim this study to compare the safety and immunogenicity of Healive® with Havrix® and live attenuated vaccines in pediatric populations. Methods: A systematic search of PubMed, Scopus, Web of Science, and Embase databases was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing Healive with other vaccines were included. Results: Seven RCTs involving 3664 patients were included. Healive showed comparable efficacy to Havrix regarding seroconversion rates and GMT at one month (SMD = 0.24, 95% CI [-0.11 to 0.59]), but achieved better results at six (SMD = 0.85, 95% CI [0.57 to 1.07]) and seven months (SMD = 0.55, 95% CI [0.41 to 0.70]). When compared to live attenuated vaccines, Healive demonstrated superior GMT at one month (SMD = 0.31, 95% CI [0.07 to 0.56]) and two years (SMD = 0.36, 95% CI [0.06 to 0.67]). Conclusion: Healive appears to be effective and safe for preventing hepatitis A, providing at least five years of protection. This review underscores the importance of ongoing research to optimize hepatitis A vaccination strategies, including standardized assays for antigen content, clarification of protective antibody levels, and large-scale trials in regions of intermediate endemicity.


  • Open Access

    Efficacy and safety of hand suturing technique application in the endoscopic treatment of gastrointestinal tract tumors: a systematic review and meta-analysis

    by Mohamed Mahmoud Marey, Abdelaziz A. Awad, Amany Mahmoud Genidy, Aliaa Bahaa Abdelaziz, Menna M. Aboelkhier, Mazen Negmeldin Aly Yassin, Mohamed A. Aldemerdash, Ahmed Aldemerdash, Mohamed Eldesouki, Abdelrahman Shata, et al.


  • Open Access

    Prophylactic mesh reinforcement in elective abdominal surgeries: a systematic review, meta-analysis, and GRADE evidence assessment

    by Ahmed W. Abbas, Mohamed F. Abo-Elsoad, Mahmoud Diaa Hindawi, Mohamed Abo Zeid, Abd-Elfattah Kalmoush, Menna M. Aboelkier, Mohamed A. Aldemerdash, Rashad G. Mohamed, Hosam Elghadban

    Background: Elective laparotomies account for a larger fraction of laparotomy procedures performed worldwide. Although surgical techniques continue to advance, the incidence of incisional hernia (IH) and other post-operative complications remain challenging to surgeons. This study aimed to evaluate the significance of using prophylactic mesh reinforcement during elective laparotomy. Methods: A comprehensive search was conducted in PubMed, Scopus, and Web of Science to identify studies that included adults undergoing elective abdominal surgery and compared prophylactic mesh reinforcement of the abdominal wall using any type of mesh in any anatomical position to standard fascial closure with sutures alone, without mesh. The analysis aimed to assess the impact of mesh reinforcement on the incidence of IH at all possible timepoints, in addition to secondary outcomes based on mesh technique, such as wound infections, dehiscence, seroma, re-operation for IH, and prolonged hospital stay. Data analysis was performed using the R programming language. Results: Fifteen RCTs, including 2,233 patients with follow-up durations ranging from 1.5 to 5 years, were analyzed. Prophylactic mesh reinforcement significantly reduced the incidence of IH following elective gastrointestinal surgeries at 12 months (risk ratio [RR] = 0.35, 95% confidence interval [CI] [0.14; 0.86], p = 0.02), 24 months (RR = 0.28, 95% CI [0.11; 0.68], p < 0.01), 36 months (RR = 0.62, 95% CI [0.36; 1.06], p = 0.08), and 48 months (RR = 0.35, 95% CI [0.11; 1.17], p = 0.09). Similarly, mesh significantly reduced IH rates following open abdominal aortic aneurysm repair at 12 months (RR = 0.13, 95% CI [0.04; 0.41], p < 0.01), 24 months (RR = 0.31, 95% CI [0.21; 0.45], p < 0.01), and 36 months (RR = 0.23, 95% CI [0.10; 0.54], p < 0.01). Conclusions: Prophylactic mesh reinforcement during elective abdominal laparotomy significantly reduced the incidence of IH and the need for reoperation. However, it is associated with an increased risk of seroma formation and, to a lesser extent, wound infection, particularly with the Sublay technique.


  • Open Access

    Efficacy and Safety of Ontamalimab in Treating Inflammatory Bowel Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Abdelaziz A. Awad, Menna M. Aboelkhier, Rashad G. Mohamed, Ahmed W. Abbas, Ahmed W. Hageen, Yousef R. Alnomani, Mohamed Abouzid

    Purpose of Review: Ontamalimab is an anti-MAdCAM-1 monoclonal antibody. It directly restricts the binding of α4β7 + lymphocytes and does not affect the homing of lymphocytes in the central nervous system. Thus, it diminishes adverse effects while blocking their migration into the gut. Several clinical trials have validated the efficacy and safety of ontamalimab for Crohn's disease and ulcerative colitis. However, to date, there is no meta-analysis on the topic. Hence, we are conducting this meta-analysis. Using R version R.3.3, we reported outcomes as risk ratios (RRs) or mean difference (MD) and confidence intervals (CIs). A P-value ≤ 0.05 is considered as statistically significant. Recent Findings: The meta-analysis included a total of three studies with 1384 patients. In patients with ulcerative colitis, compared to placebo, ontamalimab had significantly improved clinical remission (RR = 2.17, 95% CI [1.42 to 3.32], P < 0.01), clinical response (RR = 1.79, 95% CI [1.35 to 2.38], P < 0.01), endoscopic response (RR = 2.27, 95% CI [1.55 to 3.31], P < 0.01) and mucosal healing (RR = 2.39, 95% CI [1.63 to 3.50], P < 0.01). No significant differences favoring ontamalimab or the placebo were found regarding safety outcomes. In patients with Crohn's disease, ontamalimab showed superiority over placebo in endoscopic response (RR = 2.00, 95% CI [1.08 to 3.70], P = 0.03). However, ontamalimab was associated with a higher incidence of serious adverse events, and study discontinuations were due to adverse events. Summary: Ontamalimab has shown promising results, particularly in patients with moderate to severe ulcerative colitis, as evidenced by better clinical response and remission. However, questions remain about its long-term effectiveness and safety; hence, extended follow-up and more extensive studies are necessary.